Welcome to our dedicated page for Mesa Laboratories SEC filings (Ticker: MLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mesa Laboratories, Inc. (MLAB) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. Mesa is a Colorado corporation whose common stock is listed on The Nasdaq Stock Market LLC under the symbol MLAB, and it regularly submits reports and disclosures that detail its operations, governance, and financial condition.
Through this page, users can review current and historical filings such as Form 8-K reports, which Mesa uses to announce material events. Recent 8-K filings have covered topics including quarterly financial results, the creation of direct financial obligations under its credit facility, and the settlement of outstanding convertible notes. These filings often reference accompanying press releases that provide additional narrative and financial tables.
Investors can also find proxy materials, such as the company’s definitive proxy statement (DEF 14A). This document outlines items for shareholder vote at the annual meeting, including the election of directors, ratification of the independent registered public accounting firm, advisory votes on executive compensation, and amendments to equity incentive plans. The proxy statement also describes Mesa’s board committees and aspects of its executive compensation framework.
In addition to these documents, Mesa’s SEC filings reference its credit facility, leverage metrics, and other capital structure details, giving readers insight into how the company finances its operations and manages debt. Stock Titan’s interface surfaces these filings with AI-powered summaries that help explain key sections, making it easier to understand complex disclosures without reading every page.
Users interested in MLAB can use this page to monitor new filings as they are posted to EDGAR, review past disclosures, and better understand the regulatory and governance context surrounding Mesa’s life science tools and quality control business.
Mesa Laboratories President and CEO Gary M. Owens reported the expiration and forfeiture of 8,211 restricted stock units, each representing one share of common stock. The RSUs were due to vest on June 15, 2028, but were deemed expired on March 31, 2026 and returned to the issuer rather than sold on the market. Following this disposition to the company, Owens holds 16,448 restricted stock units directly.
Mesa Laboratories Inc — Schedule 13G/A (Amendment No. 6) by The Vanguard Group. The filing states that The Vanguard Group reports zero shares beneficially owned of Mesa Laboratories common stock and 0% of the class. The amendment explains an internal realignment effective January 12, 2026 that caused certain Vanguard subsidiaries or divisions to report separately and disaggregated from The Vanguard Group, Inc. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Mesa Laboratories detailed the transition of President and CEO Gary Owens, whose departure was previously announced and will be effective on or about April 13, 2026. Under a new Retention and Transition Agreement dated March 20, 2026, he will continue in a non-executive role until June 22, 2026 to support an orderly handover.
At his June 22, 2026 separation, Mr. Owens will receive severance pay and benefits consistent with a “without cause” termination and keep a pro-rated portion of his June 15, 2025 performance stock unit award, vesting at the lower of target or actual performance. He must sign a release of claims to receive these benefits. He also resigned from the board as of March 20, 2026, and the company states his resignation was not due to any disagreement over operations, policies, or practices.
Mesa Laboratories (Common Stock) Schedule 13G: Long Path-related reporting persons report beneficial ownership of 311,703 shares, representing 5.6% of the class. Percentage ownership is based on 5,524,813 shares outstanding as of January 31, 2026.
The filing lists the owner as Long Path Smaller Companies Fund, LP with affiliated entities and two co-portfolio managers joining a joint filing. The shares are directly held by the Fund and the reporting parties disclaim beneficial ownership except for pecuniary interest.
Mesa Laboratories director Shiraz Shabanali Ladiwala reported an open-market purchase of 3,500 shares of Mesa Laboratories common stock at $72.23 per share. This buy on March 10, 2026 increased his directly held position to 8,523 shares, signaling a larger personal stake in the company.
Mesa Laboratories director Mark Christopher Capone bought additional company stock in an open-market transaction. He purchased 1,301 shares of Common Stock at a price of $76.35 per share. After this purchase, he directly owns 3,429 shares of Mesa Laboratories Common Stock.
Mesa Laboratories director R. Tony Tripeny bought shares of the company in the open market. He purchased 1,315 shares of Mesa Laboratories common stock at a price of $76.00 per share. After this transaction, his direct ownership increased to 5,398 common shares.
Mesa Laboratories is making a planned leadership change. Gary Owens will step down as President and CEO around April 12–13, 2026, with the company stating his departure is not due to any disagreement over operations, policies, or practices.
The Board has appointed Dr. Siddhartha Kadia as the new President and CEO and as a director, effective April 13, 2026. Under his employment agreement, he will receive an annual base salary of $850,000, a target annual bonus equal to at least 100% of salary, and initial equity awards of RSUs valued at $3.0 million and PSUs with a target value of $3.0 million, subject to multi‑year vesting and performance conditions.
Mesa Laboratories delivered modest top-line growth with stronger profits for the nine months ended December 31, 2025. Revenue rose to $185.4 million from $178.8 million, while net income more than doubled to $10.8 million, lifting diluted EPS to $1.95 from $0.94.
Growth came mainly from Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions, while Clinical Genomics declined due to weaker demand in China. Gross margin stayed solid at 62.6%, and operating income improved to $15.8 million.
The company refinanced its 1.375% convertible notes, settling the $97.5 million principal at maturity using its credit facility, which now includes a $68.4 million term loan and $98.3 million drawn on the revolver. Cash was $29.0 million, with operating cash flow of $28.9 million and continued quarterly dividends of $0.16 per share. Management highlights ongoing macro headwinds in China and notes that the Clinical Genomics unit remains more sensitive to potential future goodwill impairment.
Mesa Laboratories, Inc. filed a current report to let investors know it has released financial results. On February 3, 2026, the company issued a press release covering its performance for the three and nine months ended December 31, 2025.
The press release is included as Exhibit 99.1 and is provided as supplemental information. The company specifies that this earnings information is being furnished, not filed, which means it is not subject to certain liability provisions of the securities laws or automatically incorporated into other securities offerings.